Holen Sie sich die Stockscreener-App
13.55
0.44%
-0.06
Vorhandelsmarkt:
13.55
Schlusskurs vom Vortag:
$13.61
Offen:
$13.7
24-Stunden-Volumen:
1.06M
Relative Volume:
1.11
Marktkapitalisierung:
$832.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-221.04M
KGV:
-3.6481
EPS:
-3.7143
Netto-Cashflow:
$-178.65M
1W Leistung:
+2.81%
1M Leistung:
-13.86%
6M Leistung:
+32.58%
1J Leistung:
+55.03%
1-Tages-Spanne:
$13.17
$13.81
1-Wochen-Bereich:
$11.68
$14.50
52-Wochen-Spanne:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
13.55 | 836.44M | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | Citigroup | Buy |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
CGEM Stock Price, Quote & Chart - ChartMill
CGEM Reiterated by Wedbush -- Price Target Maintained at $37 - GuruFocus
Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics reports remissions in SLE, RA with CLN-978 - scanx.trade
William Blair reiterates Cullinan Oncology stock rating on trial data By Investing.com - Investing.com South Africa
William Blair reiterates Cullinan Oncology stock rating on trial data - Investing.com
CGEM: CLN-978 and velinotamig show breakthrough efficacy and safety in refractory autoimmune diseases - TradingView
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune DiseasesSlideshow (NASDAQ:CGEM) 2026-06-10 - Seeking Alpha
Cullinan Therapeutics (CGEM) Reports Positive Clinical Developme - GuruFocus
CGEM: T cell engagers show robust efficacy in RA and SLE, with expanded trials planned for 2027 - TradingView
Cullinan reports clinical data for autoimmune drug candidates - Investing.com UK
CGEM: CLN-978 and velinotamig advance toward Phase 2 after strong efficacy and safety in SLE and RA - TradingView
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data - TipRanks
Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps - Moomoo
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases - The Manila Times
Cullinan Therapeutics Shares New Clinical Data Across Its - GlobeNewswire
Cullinan Therapeutics shares positive Phase 1 data for CLN-978 and velinotamig, outlines next‑stage plans - TradingView
Cullinan Therapeutics (NASDAQ: CGEM) shares new autoimmune trial results - Stock Titan
Cullinan Aims for Autoimmune 'Reset' with T Cell Engager Data - BriefGlance
Cullinan Therapeutics details new biomarker approach for immune reset in autoimmune disease research - Traders Union
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO) - The Globe and Mail
Cullinan TherapeuticsExpanding The Reach Of T Cell Engagers Beyond Cancer - RTTNews
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $38 - Moomoo
CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $30 - GuruFocus
Cullinan Therapeutics Reports Promising Phase 1 Data for CLN-978 CD19xCD3 T Cell Engager in SLE and RA at EULAR 2026 Congress - Minichart
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data - TipRanks
Cullinan Therapeutics shares Phase 1 CLN-978 data showing deep B-cell depletion and clinical responses - TradingView
Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data - Stock Titan
Cullinan Therapeutics (CGEM) Unveils Promising Phase 1 Data at E - GuruFocus
Cullinan Therapeutics (CGEM) Unveils Promising Phase 1 Data at EULAR Congress - GuruFocus
Cullinan Therapeutics Inc Cln-978 Shows Favorable Safety Profile With Single Target Doses Up To 30 Μg As Well As Initial Multi-Dose Regimen - TradingView
Cullinan Therapeutics presents initial clinical data for CLN-978 in refractory SLE and RA - Traders Union
Cullinan Therapeutics Reports Positive Clinical Data for CLN-978 in Treating Systemic Lupus Erythematosus and Rheumatoid Arthritis - Quiver Quantitative
Cullinan Therapeutics Presents Initial Clinical Data for - GlobeNewswire
Cullinan Therapeutics Presents Initial Clinical Data for Cln-978, A Cd19xcd3 T Cell Engager, At the Eular 2026 Congress - marketscreener.com
Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors - TipRanks
Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments - Traders Union
Number of shareholders of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
BTIG Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $38 - Moomoo
CGEM Technical Analysis | Trend, Signals & Chart Patterns | CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) - ChartMill
Cullinan Therapeutics (CGEM) Stock Analysis Report | Financials & Insights - Benzinga España
Cullinan Therapeutics (CGEM) Retreats 1% as Stock Approaches Support ZoneIV Percentile - The Legal Advocate
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), Cullinan Management (CGEM) - The Globe and Mail
Cullinan Therapeutics (CGEM) Plans Immunology Day Event in NYC - GuruFocus
CGEM - Finviz
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager - The Manila Times
Cullinan Therapeutics to Host Immunology Day to Showcase - GlobeNewswire
Wedbush maintains Cullinan Therapeutics (CGEM) outperform recommendation - MSN
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics, Inc. $CGEM Shares Sold by Blue Owl Capital Holdings LP - MarketBeat
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cullinan Therapeutics Inc-Aktie (CGEM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
May 05 '26 |
Sale |
14.62 |
8,000 |
116,996 |
166,844 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):